iltamiocel
Chronic Fecal Incontinence (Obstetric Anal Sphincter Injury)
Phase 3Active
Key Facts
Indication
Chronic Fecal Incontinence (Obstetric Anal Sphincter Injury)
Phase
Phase 3
Status
Active
Company
About Cook MyoSite
Cook MyoSite is a private, clinical-stage biotech leveraging over 20 years of expertise in muscle cell technology to develop regenerative therapies. Its core asset is iltamiocel, an autologous muscle-derived cell therapy with FDA RMAT designation, currently in Phase III trials for stress urinary incontinence and fecal incontinence, and Phase II/III for oropharyngeal dysphagia. The company also generates early revenue through a Laboratory Research Services division, offering characterized primary cells and custom services to the research community under an ISO9001-certified quality system.
View full company profile